Cite
HARVARD Citation
Lee, S. et al. (2021). Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leukemia & lymphoma. 62 (2), pp. 498-500. [Online].